Search results for "LUDI"

showing 10 items of 753 documents

Managing Multi-center Flow Cytometry Data for Immune Monitoring.

2014

With the recent results of promising cancer vaccines and immunotherapy 1 – 5 , immune monitoring has become increasingly relevant for measuring treatment-induced effects on T cells, and an essential tool for shedding light on the mechanisms responsible for a successful treatment. Flow cytometry is the canonical multi-parameter assay for the fine characterization of single cells in solution, and is ubiquitously used in pre-clinical tumor immunology and in cancer immunotherapy trials. Current state-of-the-art polychromatic flow cytometry involves multi-step, multi-reagent assays followed by sample acquisition on sophisticated instruments capable of capturing up to 20 parameters per cell at a…

Cancer ResearchComputer scienceData managementREST APIdata provenancecomputer.software_genrelcsh:RC254-282automated analysisData modelinglaboratory informatics03 medical and health sciences0302 clinical medicineLaboratory informaticsreproducible analysisFlow cytometry030304 developmental biologyOriginal Research0303 health sciencesApplication programming interfacebusiness.industrymetadatalcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensData scienceAutomationMetadataManagement information systemsOncologyData miningdata managementbusinesscomputer030215 immunologyCommunication channelCancer informatics
researchProduct

Brain Mapping-Aided SupraTotal Resection (SpTR) of Brain Tumors: The Role of Brain Connectivity

2021

Brain gliomas require a deep knowledge of their effects on brain connectivity. Understanding the complex relationship between tumor and functional brain is the preliminary and fundamental step for the subsequent surgery. The extent of resection (EOR) is an independent variable of surgical effectiveness and it correlates with the overall survival. Until now, great efforts have been made to achieve gross total resection (GTR) as the standard of care of brain tumor patients. However, high and low-grade gliomas have an infiltrative behavior and peritumoral white matter is often infiltrated by tumoral cells. According to these evidences, many efforts have been made to push the boundary of the re…

Cancer ResearchConnectomicsmedicine.medical_specialtyMini Reviewlow-grade gliomasBrain tumorbrain connectomelcsh:RC254-282Brain mappingResectionLesionWhite matterNeuroimagingmedicineBrain connectome Supratotal resection Brain mapping Brain tumor Connectomics Extent of resection High-grade gliomas Low-grade GliomasconnectomicsBrain GliomaSettore MED/27 - Neurochirurgiabusiness.industryAstrocytomalcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseextent of resectionmedicine.anatomical_structureOncologySuprtotal resectionbrain mappingRadiologymedicine.symptomsupratotal resectionbusinesshigh-grade gliomasbrain tumorMRI
researchProduct

Germline Predisposition to Pediatric Cancer, from Next Generation Sequencing to Medical Care

2021

Knowledge about genetic predisposition to pediatric cancer is constantly expanding. The categorization and clinical management of the best-known syndromes has been refined over the years. Meanwhile, new genes for pediatric cancer susceptibility are discovered every year. Our current work shares the results of genetically studying the germline of 170 pediatric patients diagnosed with cancer. Patients were prospectively recruited and studied using a custom panel, OncoNano V2. The well-categorized predisposing syndromes incidence was 9.4%. Likely pathogenic variants for predisposition to the patient’s tumor were identified in an additional 5.9% of cases. Additionally, a high number of pathogen…

Cancer ResearchCàncer en els infantsGenetic counselingBioinformaticsgermlineMedical careArticleDNA sequencingGermlineworking toolGenetic predispositionmedicinegenetic syndromeRC254-282genetic counselingbusiness.industryIncidence (epidemiology)Neoplasms. Tumors. Oncology. Including cancer and carcinogensCancerpediatric oncologymedicine.diseasePediatric cancerOncologyhereditary cancerbusinessgenetic predispositionGenèticaCancers
researchProduct

R-Roscovitine (Seliciclib) prevents DNA damage-induced cyclin A1 upregulation and hinders non-homologous end-joining (NHEJ) DNA repair.

2010

Abstract Background CDK-inhibitors can diminish transcriptional levels of cell cycle-related cyclins through the inhibition of E2F family members and CDK7 and 9. Cyclin A1, an E2F-independent cyclin, is strongly upregulated under genotoxic conditions and functionally was shown to increase NHEJ activity. Cyclin A1 outcompetes with cyclin A2 for CDK2 binding, possibly redirecting its activity towards DNA repair. To see if we could therapeutically block this switch, we analyzed the effects of the CDK-inhibitor R-Roscovitine on the expression levels of cyclin A1 under genotoxic stress and observed subsequent DNA damage and repair mechanisms. Results We found that R-Roscovitine alone was unable …

Cancer ResearchDNA RepairDNA repairDNA damageSettore MED/06 - Oncologia MedicaCyclin DCyclin ACyclin BSettore BIO/11 - Biologia Molecolarelcsh:RC254-282RoscovitineProtein Kinase InhibitorsBIO/10 Biochimicaroscovitine doxorubicinbiologyResearchCyclin A1; Doxorubicin; Protein Kinase Inhibitors; Purines; Up-Regulation; DNA Damage; DNA Repair; Hydrogen-Ion Concentration; Cancer Research; Molecular Medicine; OncologyG2-M DNA damage checkpointHydrogen-Ion Concentrationlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensUp-RegulationOncologyDoxorubicinPurinesCancer researchbiology.proteinMolecular MedicineCyclin A1biological phenomena cell phenomena and immunityCyclin A1Cyclin A2DNA DamageMolecular cancer
researchProduct

Aurora kinases in ovarian cancer

2020

Aurora kinases (AURK) are key regulators of the mitotic spindle formation. AURK is frequently overexpressed in ovarian cancer and this overexpression has been frequently associated with prognosis in these tumours. Interestingly, AURK have been shown to interact with DNA repair mechanisms and other cell cycle regulators. These functions have brought light to Aurora family as a potential target for anticancer therapy. In the last years, two clinical trials with different AURK inhibitors have shown activity in epithelial and clear-cell ovarian cancer. Although there is a lack of predictive factors of AURK inhibition activity, recent trials have identified some candidates. This review will focu…

Cancer ResearchDNA repairAurora inhibitorReviewCarcinoma Ovarian EpithelialProtein Serine-Threonine Kinaseslcsh:RC254-282aurora kinaseAurora kinaseAurora KinasesHumansMedicine1506Protein Kinase InhibitorsOvarian Neoplasmsbusiness.industryKinaseCell cyclemedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensSpindle apparatusClinical trialovarian cancerOncologyCancer researchFemalebusinessOvarian canceraurora inhibitorsESMO Open
researchProduct

Impact of Extracellular Acidity on the Activity of P-glycoprotein and the Cytotoxicity of Chemotherapeutic Drugs

2006

AbstractThe expression and activity of P-glycoprotein (pGP) play a role in the multidrug resistance of tumors. Because solid-growing tumors often show pronounced hypoxia or extracellular acidosis, this study attempted to analyze the impact of an acidic environment on the expression and activity of pGP and on the cytotoxicity of chemotherapeutic agents. For this, prostate carcinoma cells were exposed to an acidic extracellular environment (pH 6.6) for up to 24 hours. pGP activity was more than doubled after 3 to 6 hours of incubation in acidic medium, whereas cellular pGP expression remained constant, indicating that increased transport rate is the result of functional modulation. In paralle…

Cancer ResearchDaunorubicinPharmacologyP-glycoproteinlcsh:RC254-282Calcium in biologyExtracellularmedicinepolycyclic compoundsintracellular Ca2+ concentrationCytotoxicityacidityProtein kinase CP-glycoproteinbiologyintegumentary systemChemistrychemotoxicitylcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogenscarbohydrates (lipids)BiochemistryCell culturebiology.proteinIntracellularmedicine.drugprotein kinase CNeoplasia
researchProduct

Risk of classical Kaposi sarcoma by plasma levels of Epstein-Barr virus antibodies, sCD26, sCD23 and sCD30

2010

Abstract Background To clarify the immunological alterations leading to classical Kaposi sarcoma (cKS) among people infected with KS-associated herpesvirus (KSHV). Methods In a population-based study of 119 cKS cases, 105 KSHV-seropositive controls, and 155 KSHV-seronegative controls, we quantified plasma soluble cluster of differentiation (sCD) levels and antibodies against Epstein-Barr virus nuclear antigen-1 (anti-EBNA-1) and viral capsid antigen (anti-VCA). Differences between groups in prevalence of low-tertile anti-EBNA-1 and high-tertile anti-VCA were compared by logistic regression. Continuous levels between groups and by presence of cKS co-factors among controls were compared by li…

Cancer ResearchEpidemiologyPopulationmedicine.disease_causeSettore MED/42 - Igiene Generale E Applicatalcsh:RC254-282Viruslcsh:Infectious and parasitic diseasesDiabetes mellitusmedicinelcsh:RC109-216educationeducation.field_of_studyEpstein-Barr virus antibodiebiologyCluster of differentiationbusiness.industryKaposi sarcomasCD26 sCD23 and sCD30lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseEpstein–Barr virusInfectious DiseasesOncologyImmunologyKaposi sarcoma; Epstein-Barr virus antibodies; sCD26 sCD23 and sCD30biology.proteinSarcomaCortisoneAntibodybusinessmedicine.drugResearch ArticleInfectious Agents and Cancer
researchProduct

Stabilizing versus Destabilizing the Microtubules: A Double-Edge Sword for an Effective Cancer Treatment Option?

2015

Microtubules are dynamic and structural cellular components involved in several cell functions, including cell shape, motility, and intracellular trafficking. In proliferating cells, they are essential components in the division process through the formation of the mitotic spindle. As a result of these functions, tubulin and microtubules are targets for anticancer agents. Microtubule-targeting agents can be divided into two groups: microtubule-stabilizing, and microtubule-destabilizing agents. The former bind to the tubulin polymer and stabilize microtubules, while the latter bind to the tubulin dimers and destabilize microtubules. Alteration of tubulin-microtubule equilibrium determines th…

Cancer ResearchEpothilonesSettore MED/06 - Oncologia MedicaOmbrabulin2734Antineoplastic AgentsReview ArticleMicrotubulesPathology and Forensic Medicinechemistry.chemical_compoundMicrotubuleNeoplasmsHumansRC254-282QH573-671biologyNeoplasms. Tumors. Oncology. Including cancer and carcinogensCancer Research; Molecular Medicine; 2734; Cell BiologyCell BiologyGeneral MedicineDiscodermolideCell cycleCell biologySpindle apparatusTubulinchemistrybiology.proteinMolecular MedicineCytologyIntracellularAnalytical Cellular Pathology
researchProduct

Site-Specific Dual-Labeling of a VHH with a Chelator and a Photosensitizer for Nuclear Imaging and Targeted Photodynamic Therapy of EGFR-Positive Tum…

2021

Simple Summary Variable domains of heavy chain only antibodies are small proteins that can be used for tumor imaging and therapy upon conjugation of functional groups. As frequently used random conjugation techniques can decrease binding to the target of interest, site-specific conjugation of these functional groups is preferred. Here, we optimized site-specific conjugation of both a chelator for binding of a radiometal and a photosensitizer to epidermal growth factor receptor (EGFR) binding VHH 7D12. We characterized this dual-labeled VHH for nuclear imaging and targeted photodynamic therapy of EGFR-expressing tumors. Abstract Variable domains of heavy chain only antibodies (VHHs) are valu…

Cancer ResearchFluorescence-lifetime imaging microscopyBiodistribution[SDV.IB.IMA]Life Sciences [q-bio]/Bioengineering/Imagingmedia_common.quotation_subjectmedicine.medical_treatmentPhotodynamic therapyvariable domain of heavy chain only antibodies (VHH); site-specific conjugation; dual-labeling; nuclear imaging; photodynamic therapy[SDV.CAN]Life Sciences [q-bio]/Cancer[CHIM.THER]Chemical Sciences/Medicinal Chemistrylcsh:RC254-282Article030218 nuclear medicine & medical imaging03 medical and health sciencesTumours of the digestive tract Radboud Institute for Health Sciences [Radboudumc 14]0302 clinical medicineAll institutes and research themes of the Radboud University Medical CenterIn vivoduallabelingmedicineTumours of the digestive tract Radboud Institute for Molecular Life Sciences [Radboudumc 14]PhotosensitizerInternalizationmedia_commonnuclear imagingChemistrysite-specific conjugationlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens3. Good healthOncologyphotodynamic therapy030220 oncology & carcinogenesisUrological cancers Radboud Institute for Health Sciences [Radboudumc 15]dual-labelingBiophysicsvariable domain of heavy chain only antibodies (VHH)A431 cellsEx vivoCancers
researchProduct

Pimasertib Versus Dacarbazine in Patients With Unresectable NRAS-Mutated Cutaneous Melanoma: Phase II, Randomized, Controlled Trial with Crossover

2020

This study investigated the efficacy and safety of pimasertib (MEK1/MEK2 inhibitor) versus dacarbazine (DTIC) in patients with untreated NRAS-mutated melanoma. Phase II, multicenter, open-label trial. Patients with unresectable, stage IIIc/IVM1 NRAS-mutated cutaneous melanoma were randomized 2:1 to pimasertib (60 mg

Cancer ResearchGastroenterologypimasertiblaw.invention0302 clinical medicineRandomized controlled triallawClinical endpoint030212 general & internal medicineMalignant melanomaHazard ratioProgression-free survivalSciences bio-médicales et agricoleslcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens3. Good healthDacarbazineOncology[SDV.SP.PHARMA] Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology030220 oncology & carcinogenesismedicine.symptomPimasertibmedicine.drugQuality of lifemedicine.medical_specialtyNauseaDacarbazinemalignant melanomadacarbazine[SDV.CAN]Life Sciences [q-bio]/CancerN-(2 3-dihydroxypropyl)-1-((2-fluoro-4-iodophenyl)amino)isonicotinamideNeutropeniaN-(23-dihydroxypropyl)-1-((2-fluoro-4-iodophenyl)amino)isonicotinamidelcsh:RC254-282Article03 medical and health sciences[SDV.CAN] Life Sciences [q-bio]/CancerInternal medicinemedicineProgression-free survivalAdverse effectbusiness.industry[SDV.MHEP.DERM] Life Sciences [q-bio]/Human health and pathology/Dermatologymedicine.diseaseadverse eventsCancérologiequality of lifeAdverse events[SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacologybusinessprogression-free survival[SDV.MHEP.DERM]Life Sciences [q-bio]/Human health and pathology/Dermatology
researchProduct